Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine. | ||
 Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates Zealand Pharma AS (ZLDPF) delivered earnings and revenue surprises of +2,150.00% and +756.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Zealand Pharma (CPSE:ZEAL) Stock Looks Fairly Valued After Its 90% Five Year Run Zealand Pharma stock has delivered a strong 90.3% return over the past five years, yet its low overall value score and current market multiples suggest the shares may now be closer to fairly priced than a clear bargain. Over five years, Zealand Pharma has returned 90.3%, which puts current buyers in a different position to those who entered earlier in the story. The recent $100 million royalty deal with Royalty Pharma can support funding for rusfertide and other priorities. Reliance on... | ||
Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value Debate Why Zealand Pharma stock is in focus after the Royalty Pharma deal Zealand Pharma (CPSE:ZEAL) has drawn fresh attention after agreeing to a US$100 million royalty purchase and sale deal with Royalty Pharma linked to rusfertide, a potential treatment for polycythemia vera. The agreement transfers Zealand Pharma's economic interests related to rusfertide, including potential future royalty rights. It also provides new funding that management plans to redeploy toward the company's key priorities... | ||
 Techne (TECH) Q4 Earnings Meet Estimates Techne (TECH) delivered earnings and revenue surprises of 0.00% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of -30.77% and -10.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -8.57% and -32.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates Ultragenyx (RARE) delivered earnings and revenue surprises of +29.13% and +18.23%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||